Anonymous Client B — Specialty pharmaceutical company ($400M revenue, entering rare disease therapeutics)
The client's leadership saw rare diseases as an attractive growth area due to orphan drug incentives, lower competitive intensity, and premium pricing. However, the rare disease landscape is notoriously difficult to navigate — patient populations are poorly quantified, clinical trial recruitment is challenging, and payer willingness-to-pay varies dramatically. The company had no prior rare disease experience and needed a comprehensive framework to evaluate and prioritize 15 candidate indications.
A specialty pharmaceutical company with established products in dermatology and cardiology planned to diversify into rare diseases but had no framework for selecting which indications to pursue. Their leadership team had identified 15+ rare diseases of interest based on anecdotal market reports, but lacked systematic analysis of patient populations, competitive intensity, regulatory pathways, pricing potential, and development feasibility. Without a structured approach, they risked investing $50-100M in development programs targeting indications with limited commercial potential or insurmountable competition.
We conducted a systematic indication assessment across 15 rare diseases, evaluating each across 6 dimensions: patient population size and growth, current treatment gap and unmet need, competitive intensity and pipeline density, regulatory pathway complexity and orphan drug designation potential, pricing and reimbursement landscape, and development feasibility including trial design and recruitment. Our team leveraged epidemiological databases, regulatory databases, and our proprietary drug intelligence platform covering 100K+ drugs.
Epidemiological analysis: Estimated patient populations for 15 rare diseases across 7 major markets using prevalence data, genetic mutation rates, and diagnostic awareness factors
Competitive landscape mapping: Identified all approved drugs, pipeline assets, and clinical trials for each indication using our drug database (100K+ records) and ClinicalTrials.gov data
Regulatory pathway assessment: Evaluated orphan drug designation eligibility, accelerated approval pathways, and precedent approvals for each indication across FDA, EMA, and PMDA
Pricing benchmarking: Analyzed pricing of approved orphan drugs in comparable indications, including payer coverage status and reimbursement restrictions
Development feasibility scoring: Assessed trial design complexity, patient recruitment difficulty, endpoint selection challenges, and CMC requirements
Prioritization framework: Combined all dimensions into a weighted scoring model with sensitivity analysis to identify top 5 indications
We delivered a prioritized shortlist of 5 rare disease indications with detailed market entry roadmaps. The top 5 indications were selected based on a combination of high unmet need, manageable competition, favorable regulatory pathways, and strong pricing potential. For each prioritized indication, we provided a detailed development roadmap, competitive positioning strategy, and preliminary pricing recommendation.
Phase 1 (Weeks 1-3): Epidemiological analysis and patient population sizing for 15 rare diseases across 7 major markets
Phase 2 (Weeks 2-5): Competitive landscape mapping and pipeline analysis using our drug intelligence platform
Phase 3 (Weeks 4-7): Regulatory pathway assessment and pricing benchmarking for each indication
Phase 4 (Weeks 6-8): Development feasibility scoring and weighted prioritization framework
Phase 5 (Weeks 8-10): Market entry roadmaps for top 5 indications with investment projections
| Metric | Before | After | Impact |
|---|---|---|---|
| Candidate Indications | 15 (unstructured list) | 5 (prioritized with roadmaps) | Focused R&D investment on highest-potential indications |
| Combined Addressable Market | Unknown | $2.3B (5-year) | Quantified market opportunity for board investment decision |
| Average Competitive Density | Not assessed | Low-Medium (top 5) | Selected indications with favorable competitive windows |
| Orphan Drug Designation Probability | Unclear | High (4 of 5) | 4 indications likely eligible for orphan incentives |
| Development Investment Clarity | No estimates | $50-80M per program | Clear capital requirements for each prioritized indication |
“We were about to commit $60M to a rare disease program based on a consultant's recommendation. Medifirm's systematic analysis showed that indication had 4 competing programs in Phase III. They redirected us to two indications with virtually no competition and clear orphan drug pathways. That pivot saved us from entering a crowded market.”
Chief Strategy Officer
Anonymous Client B
Forecast
Combined addressable market across 5 prioritized rare disease indications projected to reach $2.3B by 2031, driven by orphan drug pricing and unmet need.
Every engagement starts with understanding your unique strategic challenge. Partner with Medifirm to transform data into decisions.